Sometimes restraint is the wiser choice — half of patients are cured with PD-1 alone.
Curated science + real conversations = faster, safer implementation on Monday.
A hopeful reflection on RP1’s FDA setback and the future of intratumoral therapy in melanoma.
When innovation meets immune activation, new possibilities emerge for melanoma care.
Targeting PRAME with TCR-T cell therapy may mark a new era for immunotherapy in melanoma and beyond.
Hope isn’t always about cure — sometimes, it’s just the strength to try.
Rare immune toxicities can be fatal—but timely recognition and aggressive care can change the outcome.
When the scan isn’t the whole story, a biopsy can rewrite the ending.
The CHALLENGE trial proves what we’ve long suspected: structured exercise isn’t just good for you—it can save your life.
Cannabis can ease the journey through cancer treatment—but it is not without risks, especially when it comes to immunotherapy.